Comparing lamivudine plus dolutegravir and bictegravir/emtricitabine/ tenofovir alafenamide in antiretroviral therapynaive HIV-infected patients: preliminary results from clinical practice

被引：0
|
作者：
Long, H. [1 ]
机构：
[1] Guiyang Publ Hlth Clin Ctr, Guiyang, Peoples R China
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
406
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [1] Comparing Lamivudine plus Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice
    Baldin, Gianmaria
    Ciccullo, Arturo
    Lombardi, Francesca
    D'Angelillo, Anna
    Dusina, Alex
    Emiliozzi, Arianna
    Farinacci, Damiano
    Moschese, Davide
    Picarelli, Chiara
    Borghetti, Alberto
    Di Giambenedetto, Simona
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2021, 37 (06) : 429 - 432
  • [2] Comparison of dolutegravir plus Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice
    Gan, Lin
    Xie, Xiaoxin
    Fu, Yanhua
    Yang, Xiaoyan
    Ma, Shujing
    Kong, Linghong
    Song, Chunli
    Song, Yebing
    Ren, Tingting
    Long, Hai
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (10) : 877 - 884
  • [3] Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir
    Calza, Leonardo
    Bon, Isabella
    Pensalfine, Giulia
    Vitale, Salvatore
    Appolloni, Lucia
    Viale, Pierluigi
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 91 (04) : E9 - E11
  • [4] Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir and abacavir/lamivudine OVERRIDE
    Ustianowski, A.
    Molina, J-M
    Ward, D.
    Stellbrink, H. J.
    Podzamczer, D.
    Brinson, C.
    Custodio, J.
    Liu, H.
    Andreatte, K.
    Martin, H.
    Quirk, E.
    HIV MEDICINE, 2018, 19 : S29 - S30
  • [5] Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults
    Mendoza, Ines
    Lazaro, Alicia
    Espinosa, Alfredo
    Sanchez, Lorenzo
    Horta, Ana Maria
    Torralba, Miguel
    PLOS ONE, 2023, 18 (09):
  • [6] Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice
    Ciccullo, Arturo
    Baldin, Gianmaria
    Borghi, Vanni
    Oreni, Letizia
    Lagi, Filippo
    Fusco, Paolo
    Giacomelli, Andrea
    Torti, Carlo
    Sterrantino, Gaetana
    Mussini, Cristina
    Antinori, Spinello
    Di Giambenedetto, Simona
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2024, 63 (01)
  • [7] Outcomes after switching from 144 weeks of blinded dolutegravir/abacavir/lamivudine or dolutegravir plus emtricitabine/tenofovir alafenamide to 96 weeks of open-label bictegravir/emtricitabine/tenofovir alafenamide
    Orkin, Chloe
    Antinori, Andrea
    Rockstroh, Juergen
    Guillen, Santiago Moreno
    Martorell, Claudia
    Molina, Jean-Michel
    Lazzarin, Adriano
    Maggiolo, Franco
    Yazdanpanah, Yazdan
    Andreatta, Kristen
    Huang, Hailin
    Hindman, Jason
    Martin, Hal
    Baeten, Jared
    Pozniak, Anton
    HIV MEDICINE, 2023, 24 : 21 - 22
  • [8] Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir
    Calza, Leonardo
    Borderi, Marco
    Colangeli, Vincenzo
    Miani, Teresa
    Nuti, Bianca
    Bon, Isabella
    Lazzarotto, Tiziana
    Viale, Pierluigi
    AIDS, 2022, 36 (01) : 153 - 155
  • [9] Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide
    Scevola, Sofia
    Niubo, Jordi
    Domingo, Pere
    Verdejo, Guillermo
    Curran, Adrian
    Diaz-Brito, Vicens
    Penafiel, Judith
    Tiraboschi, Juan
    Morenilla, Sandra
    Garcia, Benito
    Soriano, Irene
    Podzamczer, Daniel
    Imaz, Arkaitz
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 (07): : 919 - 925
  • [10] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV
    Martin-Zaragoza, Lorena
    Sanchez-Rubio-Ferrandez, Javier
    Onteniente-Gonzalez, Alberto
    Gomez-Bermejo, Marcos
    Rodriguez-Alvarez, Sergio Julio
    Monereo-Alonso, Alfonso
    Molina-Garcia, Teresa
    FARMACIA HOSPITALARIA, 2024, 48 (04) : T171 - T175
12345